BGB-3111_BGB-A317_Study_001

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Beigene Study ID info

BGB-3111_BGB-A317_Study_001

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan